Skip to main content
. 2022 Jan;23(1):221–232. doi: 10.31557/APJCP.2022.23.1.221

Table 4.

The Association between the Significant Genotypes of “rs9642880” with Bladder Cancer Risk

rs9642880 Associations Risk assessment
GT TT aP. value OR 95% C.I bP. value
n=9 n=51
Sex Female 3 (33.3%) 12 (23.5%) 0.02* 1.09 0.969 - 1.226 0.1
Male 6 (66.7%) 39 (76.5%)
Bilhariziasis Negative 3 (33.3%) 18 (35.3%) 0.6 0.917 0.204 - 4.109 0.9
Positive 6 (66.7%) 33 (64.7%)
Smoker No 3 (33.3%) 15 (29.4%) 0.5 1.2 0.265 - 5.438 0.8
Yes 6 (66.7%) 36 (70.6%)
Clinical Ex. T1 0 (0.0%) 6 (11.8%) 0.2 - - -
T2 6 (66.7%) 21 (41.2%) 0.01* 3.5 1.413 - 8.672 0.01*
T3 3 (33.3%) 24 (47.1%) 0.001** 8 2.409 - 26.567 0.001**
Cytology Negative 6 (66.7%) 15 (29.4%) 0.03* 4.8 1.059 - 21.753 0.04*
Positive 3 (33.3%) 36 (70.6%)
Histopathological
characteristics
Scc 3 (33.3%) 15 (29.4%) 0.5 1.2 0.265 - 5.438 0.8
UC 6 (66.7%) 36 (70.6%)
Stage NMIBC 0 (0.0%) 3 (5.9%) 0.4 - - -
MIBC 9 (100.0%) 42 (82.4%) 0.02* 1.667 2.272 - 7.587 0.1
Superficial bladder cancer 0 (0.0%) 6 (11.8%) 0.2 - - -
Serum Creatinine Normal 6 (66.7%) 39 (76.5%) 0.4 0.615 0.133 - 2.841 0.5
High 3 (33.3%) 12 (23.5%)
Lymph Node Negative 0 (0.0%) 27 (52.9%) 0.03* 0.111 0.013 - 0.954 0.06
Positive 9 (100.0%) 24 (47.1%)
Tumor Grade GI 0 (0.0%) 6 (11.8%) 0.2 - - -
GII 3 (33.3%) 15 (29.4%) 0.4 1.035 1.448 - 10.271 0.5
GIII 6 (66.7%) 30 (58.8%) 0.1 1.123 2.081 - 8.013 0.2

SCC, squamous cell carcinoma; TCC, non-papillary transitional cell carcinoma; Ta, Superficial bladder cancer; NMIBC, Non muscle invasive bladder cancer; MIBC, Muscle invasive bladder cancer; OR, Odds Ratio; CI, Confidence Interval; *P value ≤ 0.05 significant; **P value ≤ 0.01 highly significant; aP. Value is depending on the X2 test, while bP. Value is depending onLogistic Regression analysis.